How to Adjust Anticoagulant Dosing

Slides:



Advertisements
Similar presentations
Pages 645 to 724 Mechanisms of Drug Interaction Pharmacokinetic –Reduced rate and/or completeness of absorption –Altered bioavailabilty –Reduced.
Advertisements

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Time to Cost-Effectiveness Following Stroke Reduction.
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients—Analysis of Pharmaceuticals and Medical Devices Agency Data 
Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
The ABCs of AF.
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
The Nurse View.
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF
Management Considerations in Epilepsy Among Long-Term Care Residents
REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?
Understanding Statin Metabolism
Oral Anticoagulants in AFa,b A Brief History.
Selecting NOACs for High-Risk Patients
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
The Essentials for Secondary Stroke Prevention
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Seizures in the Elderly: Treatment and Special Considerations
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
Adherence in SPAF: Measures to Improve Care
Learning Objectives Classification of VTE Goals of VTE Treatment.
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Targeting BTK Signaling in B-Cell Malignancies
Oral Anticoagulation in AF
Dos and Don’ts for High-Risk Elderly Patients With AF
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Taking the "Cryptogenic" Out of Cryptogenic Stroke
NOACs in AF: Consequences of Underdosing and NonAdherence
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Identifying High-Risk AF Patients
Long-Term Treatment of VTE: Case Studies
A Time for Change for Managing Patients With VTE Who Have Cancer
What You Didn't Know About AF and Renal Dysfunction
A Case Challenge.
New European Anticoagulant Approvals Will They Affect Practical Guidance?
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Updates in Anticoagulation: Key Sessions at ESC 2017
NOAC Studies in VTE AF Studies Superior Outcomes.
NOACs in AF: Consequences of Underdosing and NonAdherence
The ABCs of AF.
Taking the "Cryptogenic" Out of Cryptogenic Stroke
5 Good Minutes on Atrial Fibrillation-related Stroke
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
How to Adjust Anticoagulant Dosing
Antiarrhythmic Drugs in AF
Uptitration of Medications in HF: Start Low but Aim High and Stay High
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Extraordinary Cases in Stroke Prevention
What's New in NOACs in AF?.
Treating Pulmonary Embolism Today
Presentation transcript:

How to Adjust Anticoagulant Dosing

TTR Rates of Ischemic and Hemorrhagic Stroke

Key Pharmacokinetics of NOACs Absorption, Distribution, Metabolism, Excretiona-d

NOAC Dosing Considerations in Patients With Renal Dysfunction*

Situations Where an Assay for NOAC Might Be Useful

NOAC AF Studies Superior Safety Outcomes

Drug-Drug Interactions With NOACs

Assays For NOACs

Pitfalls of Assay Interpretation

NOAC Dose Comparisons

NOACs in Renal Dysfunction Approved European Labels

Discontinuation of NOACs Pre- Procedure

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.